



LABORATORIES

Patient Name: **Smith, Jane**

Sex: Male Female

Date of Birth: 5/25/1944

Specimen: Peripheral Blood

Collected: 2/24/2010

Received: 2/24/2010

Reported: 3/03/2010

Accession Number: **Σ10 - 000075**

CGI ID No.: 15243

Ordering Physician: The BEST Doctor

Client Account No.: NJ97584

Client Address: 201 Route 17 North
Rutherford, NJ 07070

Telephone: 201-528-9200

Σ SUMMATION REPORT

CLINICAL DATA: R/O myeloproliferative disorder. CBC results from 05/12/2010 are as follows: WBC: 19.3 K/uL, Hgb: 9.5 g/dL, HCT: 29.9%, MCV: 105.7 fL, Platelet: 401K/uL. Differential: 72.2% lymphocytes, 3.3% monocytes, 24.5% granulocytes.

FINAL DIAGNOSIS

Leukocytosis, and macrocytic anemia, with left-shifted myeloid maturation and rare blasts (2%), consistent with a myelodysplastic/myeloproliferative neoplasm, with abnormal karyotype (deletion 20q); BCR-ABL fusion negative; and Jak2 V617F mutation positive.

COMMENTS

Bone marrow biopsy is recommended to rule out transformation to acute leukemia. Clinical follow up is recommended.

MORPHOLOGY

Leukocytosis, and macrocytic anemia, with left-shifted myeloid maturation and rare blasts, consistent with a myelodysplastic/myeloproliferative neoplasm.

FLOW CYTOMETRY

The blast count is approximately 2%. A small population of mature myeloid cells show aberrant CD56 expression, suggestive of dysmyelopoiesis. There is no evidence for a monoclonal B or unusual T cell population.

KARYOTYPE

46,XX,del(20)(q11.2)[11]


The observed chromosome analysis revealed deletion of long arm of chromosome 20 in 11 metaphases. Deletion 20q is commonly seen in various types of hematopoietic malignancies (i.e. MDS, MPD, and ANLL).

FISH


Abnormal MDS FISH Panel, with deletion of 20q. Negative for BCR/ABL fusion.

MOLECULAR


Jak2 V617 mutation: Positive




Flow Plot of CD45 vs SS



Karyotype 46,XX,del(20)(q11.2)



FISH Del (20)q12



JAK2V617F mutation 11%

Electronically signed by:

_____, M.D.

Hematopathologist

Date: 3/03/2010

The tests utilizing analyte-specific reagents (ASR) were developed and their performance characteristics determined by Cancer Genetics, Inc. as required by CLIA '88 regulations. They have not been cleared or approved for specific uses by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. Cancer Genetics, Inc., 201 Route 17 North, Rutherford, NJ 07070. Phone number: (888) 334 - 4988 CLIA#:31D1038733; CAP LAP#: 7191582



Cancer Genetics, Inc.
Meadows Office Complex
201 Route 17 North, 2nd Floor
Rutherford, NJ 07070
T: +1.201.528.9200
E: contact@cancergenetics.com

About Cancer Genetics

Cancer Genetics, Inc. (CGI) is a full-service cytogenetics and specialized anatomic pathology laboratory, focused on providing comprehensive diagnostic, prognostic, therapeutic, and disease-monitoring information on hematopoietic malignancies and solid tumors.

Our services in cancer testing are supported by research and the highest technical quality derived from a panel of prominent scientific and medical advisors in this field – all focused on personalized care for the patient. CGI is committed to its mission of **Empowering Personalized Cancer Treatment™**.

Personalized Service

CGI's dedicated staff takes pride in our client-oriented attitude, oncology-focused reference laboratory services, superior turnaround time, enhanced reporting capabilities, electronic medical record (EMR) integration, and ongoing research and development for new tests. Our cutting-edge proprietary tests provide critical genomic information to clinicians to assist with diagnosis, prognosis, and therapeutic guidance of urogenital and HPV-associated cancers and hematological malignancies such as our CLL CompleteSM test menu. This menu provides valuable results to risk-stratify individual patients for disease progression, response to treatment, and overall prognosis of Chronic Lymphocytic Leukemia (CLL).



Technical and Professional Diagnostic and Prognostic Services

SummationSM is our proprietary comprehensive one page color diagnostic summary report. By choosing SummationSM, our hematopathologist will work up the case based on the clinical information and diagnosis provided. Our SummationSM report integrates IHC, flow cytometry, cytogenetics, FISH and molecular genetic test results into a concise and clinically relevant summary that:

- Provides comprehensive diagnostic information
- Utilizes user-friendly and easy to interpret format
- Offers appropriate patient management information

Test Methodologies

- **Flow Cytometry**
- **Anatomical Pathology**
- **Cytogenetics**
 - Chromosomal G-Banding
 - FISH, including Enriched Plasma Cells FISH
- **Molecular Diagnostics**
 - PCR and Sequencing
 - Pyrosequencing
 - CGH-Microarray